JP7055794B2 - クローディン発現がん疾患の処置のためのクローディン6又はクローディン18.2とcd3とに結合する二重特異的三価抗体 - Google Patents

クローディン発現がん疾患の処置のためのクローディン6又はクローディン18.2とcd3とに結合する二重特異的三価抗体 Download PDF

Info

Publication number
JP7055794B2
JP7055794B2 JP2019515626A JP2019515626A JP7055794B2 JP 7055794 B2 JP7055794 B2 JP 7055794B2 JP 2019515626 A JP2019515626 A JP 2019515626A JP 2019515626 A JP2019515626 A JP 2019515626A JP 7055794 B2 JP7055794 B2 JP 7055794B2
Authority
JP
Japan
Prior art keywords
cancer
binding
amino acid
cell
cldn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019515626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535234A (ja
JP2019535234A5 (cg-RX-API-DMAC7.html
Inventor
ウグール・ザヒン
クリスティアーネ・シュタードラー
レイラ・フィッシャー
アルネ・イェントレツキー
ウズレム・テュレチ
ファブリス・ル・ギャル
マリア・クロイツベルク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of JP2019535234A publication Critical patent/JP2019535234A/ja
Publication of JP2019535234A5 publication Critical patent/JP2019535234A5/ja
Priority to JP2022063389A priority Critical patent/JP7436552B2/ja
Application granted granted Critical
Publication of JP7055794B2 publication Critical patent/JP7055794B2/ja
Priority to JP2024017454A priority patent/JP7791916B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019515626A 2016-09-23 2017-09-20 クローディン発現がん疾患の処置のためのクローディン6又はクローディン18.2とcd3とに結合する二重特異的三価抗体 Active JP7055794B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022063389A JP7436552B2 (ja) 2016-09-23 2022-04-06 クローディン発現がん疾患の処置のためのクローディン6又はクローディン18.2とcd3とに結合する二重特異的三価抗体
JP2024017454A JP7791916B2 (ja) 2016-09-23 2024-02-07 クローディン発現がん疾患の処置のためのクローディン6又はクローディン18.2とcd3とに結合する二重特異的三価抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2016/072688 WO2018054484A1 (en) 2016-09-23 2016-09-23 Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
EPPCT/EP2016/072688 2016-09-23
PCT/EP2017/073773 WO2018054973A1 (en) 2016-09-23 2017-09-20 Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022063389A Division JP7436552B2 (ja) 2016-09-23 2022-04-06 クローディン発現がん疾患の処置のためのクローディン6又はクローディン18.2とcd3とに結合する二重特異的三価抗体

Publications (3)

Publication Number Publication Date
JP2019535234A JP2019535234A (ja) 2019-12-12
JP2019535234A5 JP2019535234A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7055794B2 true JP7055794B2 (ja) 2022-04-18

Family

ID=57003498

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019515626A Active JP7055794B2 (ja) 2016-09-23 2017-09-20 クローディン発現がん疾患の処置のためのクローディン6又はクローディン18.2とcd3とに結合する二重特異的三価抗体
JP2022063389A Active JP7436552B2 (ja) 2016-09-23 2022-04-06 クローディン発現がん疾患の処置のためのクローディン6又はクローディン18.2とcd3とに結合する二重特異的三価抗体
JP2024017454A Active JP7791916B2 (ja) 2016-09-23 2024-02-07 クローディン発現がん疾患の処置のためのクローディン6又はクローディン18.2とcd3とに結合する二重特異的三価抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022063389A Active JP7436552B2 (ja) 2016-09-23 2022-04-06 クローディン発現がん疾患の処置のためのクローディン6又はクローディン18.2とcd3とに結合する二重特異的三価抗体
JP2024017454A Active JP7791916B2 (ja) 2016-09-23 2024-02-07 クローディン発現がん疾患の処置のためのクローディン6又はクローディン18.2とcd3とに結合する二重特異的三価抗体

Country Status (14)

Country Link
US (2) US11787862B2 (cg-RX-API-DMAC7.html)
EP (2) EP4043494A1 (cg-RX-API-DMAC7.html)
JP (3) JP7055794B2 (cg-RX-API-DMAC7.html)
KR (2) KR102537091B1 (cg-RX-API-DMAC7.html)
CN (2) CN110023336B (cg-RX-API-DMAC7.html)
AU (3) AU2017331331B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019002168A2 (cg-RX-API-DMAC7.html)
CA (1) CA3034186A1 (cg-RX-API-DMAC7.html)
IL (3) IL264233B (cg-RX-API-DMAC7.html)
MX (2) MX2019003350A (cg-RX-API-DMAC7.html)
NZ (1) NZ750132A (cg-RX-API-DMAC7.html)
SG (1) SG11201901899PA (cg-RX-API-DMAC7.html)
WO (2) WO2018054484A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201900962B (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
EP3808376A4 (en) * 2018-06-17 2021-09-01 L&L Biopharma Co., Ltd. CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF
EP3824096A4 (en) * 2018-07-18 2022-04-20 AskGene Pharma Inc. NOVEL ANTIBODIES AND METHODS FOR THE PRODUCTION AND USE THEREOF
BR112021002032A2 (pt) * 2018-08-03 2021-07-20 Amgen Research (Munich) Gmbh construtos de anticorpos para cldn18.2 e cd3
US20210380680A1 (en) * 2018-12-07 2021-12-09 ZLlP HOLDING LIMITED Anti-claudin antibodies and uses thereof
KR20210109520A (ko) * 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 및 이의 용도
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
JP2022523749A (ja) * 2019-02-01 2022-04-26 クレージュ メディカル カンパニー,リミテッド Tcr融合タンパク質およびtcr融合タンパク質を発現する細胞
CN119708241A (zh) 2019-02-15 2025-03-28 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
WO2020205331A1 (en) * 2019-03-29 2020-10-08 Phanes Therapeutics, Inc. Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
MX2021011489A (es) * 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
KR102239781B1 (ko) * 2019-04-08 2021-04-13 주식회사 녹십자 Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
CN117659190A (zh) 2019-05-16 2024-03-08 启愈生物技术(上海)有限公司 抗cldn抗体及其药物组合物和检测方法
JP7359864B2 (ja) * 2019-07-10 2023-10-11 中外製薬株式会社 クローディン6結合分子およびその使用
CN114364701A (zh) * 2019-07-17 2022-04-15 加利福尼亚大学董事会 密封蛋白18抗体和治疗癌症的方法
US11261259B2 (en) * 2019-08-12 2022-03-01 I-Mab Biopharma Us Limited Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof
PH12022552323A1 (en) * 2020-03-31 2023-12-04 Chugai Pharmaceutical Co Ltd Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
WO2021237717A1 (zh) * 2020-05-29 2021-12-02 武汉友芝友生物制药有限公司 抗cldn18.2和cd3的双特异性抗体
CA3178855A1 (en) * 2020-06-19 2021-12-23 Innovent Biologics (Suzhou) Co., Ltd. Anti-claudin18.2 antibody and use thereof
EP4545569A3 (en) * 2020-06-30 2025-10-08 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
CN114106195B (zh) * 2020-08-27 2024-09-17 盛禾(中国)生物制药有限公司 一种多功能融合蛋白及其用途
CA3200865A1 (en) * 2020-09-29 2022-04-07 Innovent Biologics (Suzhou) Co., Ltd. Anti-claudin18.2 and cd3 bispecific antibody and use thereof
EP4240770A1 (en) * 2020-11-06 2023-09-13 Amgen Research (Munich) GmbH Polypeptide constructs selectively binding to cldn6 and cd3
CN117120477A (zh) * 2020-11-10 2023-11-24 上海齐鲁制药研究中心有限公司 针对密蛋白18a2和cd3的双特异性抗体及其应用
EP4305067A1 (en) * 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
CN114853897B (zh) * 2021-04-15 2024-01-26 北京大学深圳研究生院 抗cd19/cd22/cd3三特异性抗体及用途
US20240294640A1 (en) * 2021-06-02 2024-09-05 Qure Biotechnology (Shanghai) Co., Ltd. Anti-cd3 antibody variant, fusion protein, and application
JP7901102B2 (ja) * 2021-06-15 2026-08-05 ゼンコア インコーポレイテッド クローディン18.2及びcd3に結合するヘテロ二量体抗体
WO2022262959A1 (en) * 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Bispecific binding agents binding to cldn18.2 and cd3
IL309495A (en) * 2021-07-15 2024-02-01 BioNTech SE Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers
WO2023010068A2 (en) * 2021-07-28 2023-02-02 Cartesian Therapeutics, Inc. Multiprotein-engineered cells secreting a multispecific antibody
AU2023245103A1 (en) * 2022-03-28 2024-10-24 Fortvita Biologics (Singapore) Pte. Ltd. Preparations containing anti-claudin18.2/cd3 bispecific antibody, preparation method therefor and use thereof.
US12698336B2 (en) 2022-04-28 2026-08-04 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-human CD73 monoclonal antibody without hook effect
EP4532562A2 (en) * 2022-06-01 2025-04-09 Integral Molecular, Inc. Claudin 18.2 antibodies, methods of making the same, and uses thereof
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
JP2026501506A (ja) * 2022-12-14 2026-01-16 アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ Cldn18.2及びcd3に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
WO2024184810A1 (en) * 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2024197709A1 (zh) * 2023-03-30 2024-10-03 中国科学院深圳先进技术研究院 一种t细胞衔接器及其制备方法和应用
CN116087069B (zh) * 2023-04-10 2023-08-08 苏州药明康德新药开发有限公司 一种基于流式细胞术检测特定细胞群体组蛋白甲基化和乙酰化修饰水平的方法
WO2024243093A2 (en) * 2023-05-19 2024-11-28 The Regents Of The University Of California Multispecific antibodies targeting cd3 and cd22
KR20260015262A (ko) 2023-05-25 2026-02-02 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 클라우딘-6 접합체의 투여량
KR20240176948A (ko) * 2023-06-15 2024-12-26 에이비온 주식회사 소세포폐암 진단 및 치료를 위한 타겟으로서 클라우딘-3의 용도
WO2025120866A1 (en) * 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
AR134560A1 (es) * 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2025162454A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体和细胞因子融合蛋白及其应用
WO2025231015A1 (en) * 2024-04-30 2025-11-06 Context Therapeutics Inc. Compositions comprising bispecific antibodies that bind to claudin 6 and cd3, and uses thereof
US20250333499A1 (en) * 2024-04-30 2025-10-30 Context Therapeutics Inc. Bispecific antibodies and methods of using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500059A (ja) 2012-11-13 2016-01-07 バイオエヌテック アーゲーBioNTech AG クローディンを発現するガン疾患を処置するための剤
WO2016097408A1 (en) 2014-12-19 2016-06-23 Biotecnol Limited Fusion protein comprising three binding domains to 5t4 and cd3
WO2016135239A1 (en) 2015-02-25 2016-09-01 Biotecnol Limited Fusion protein comprising three binding domains to her2

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
CN1326881C (zh) 2003-09-29 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 一种三价双特异性抗体,其制备方法及用途
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US9605084B2 (en) * 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
ES2699753T3 (es) * 2014-01-29 2019-02-12 Biontech Ag Mimótopos peptídicos de claudina 18.2 y sus usos
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
WO2016087416A1 (en) * 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2022262959A1 (en) * 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Bispecific binding agents binding to cldn18.2 and cd3

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500059A (ja) 2012-11-13 2016-01-07 バイオエヌテック アーゲーBioNTech AG クローディンを発現するガン疾患を処置するための剤
WO2016097408A1 (en) 2014-12-19 2016-06-23 Biotecnol Limited Fusion protein comprising three binding domains to 5t4 and cd3
WO2016135239A1 (en) 2015-02-25 2016-09-01 Biotecnol Limited Fusion protein comprising three binding domains to her2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MERTENS, N.,BISPECIFIC ANTIBODIES,2011年,pp.135-149
STADLER, C., et al.,ONCOIMMUNOLOGY,2013年03月21日,Vol.5, No.3,e1091555(pp.1-12),doi: 10.1080/2162402X.2015.1091555

Also Published As

Publication number Publication date
RU2019112165A (ru) 2020-10-23
WO2018054484A1 (en) 2018-03-29
ZA202002471B (en) 2021-09-29
BR112019002168A2 (pt) 2019-09-17
SG11201901899PA (en) 2019-04-29
CN110023336B (zh) 2024-05-17
US11787862B2 (en) 2023-10-17
WO2018054973A1 (en) 2018-03-29
AU2025202697A1 (en) 2025-05-08
IL290234A (en) 2022-03-01
NZ750132A (en) 2023-05-26
MX2023005375A (es) 2023-05-22
AU2017331331B2 (en) 2022-03-10
JP7436552B2 (ja) 2024-02-21
IL290230A (en) 2022-03-01
KR102537091B1 (ko) 2023-05-31
JP2019535234A (ja) 2019-12-12
IL264233A (en) 2019-02-28
JP2024054250A (ja) 2024-04-16
KR20190052002A (ko) 2019-05-15
EP3515939A1 (en) 2019-07-31
AU2017331331A1 (en) 2019-02-07
RU2019112165A3 (cg-RX-API-DMAC7.html) 2021-01-20
JP2022091973A (ja) 2022-06-21
JP7791916B2 (ja) 2025-12-24
CN110023336A (zh) 2019-07-16
CA3034186A1 (en) 2018-03-29
ZA201900962B (en) 2020-10-28
MX2019003350A (es) 2019-08-12
KR20230074637A (ko) 2023-05-30
IL264233B (en) 2022-03-01
AU2022200283A2 (en) 2022-04-21
AU2022200283A1 (en) 2022-02-17
US20190309067A1 (en) 2019-10-10
EP4043494A1 (en) 2022-08-17
CN118388656A (zh) 2024-07-26
US20240158501A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
JP7436552B2 (ja) クローディン発現がん疾患の処置のためのクローディン6又はクローディン18.2とcd3とに結合する二重特異的三価抗体
US20240228616A1 (en) Agents for Treatment of Claudin Expressing Cancer Diseases
CA2953816C (en) Il-15-based molecules and methods of use thereof
EP2920209B1 (en) Agents for treatment of claudin expressing cancer diseases
RU2798988C2 (ru) Биспецифические трехвалентные антитела, связывающиеся с клаудином 6 или клаудином 18.2, и cd3, для лечения онкологических заболеваний с экспрессией клаудина
HK40078730A (en) Bispecific trivalent antibodies binding to claudin 6 or claudin 18.2 and cd3 for treatment of claudin expressing cancer diseases
HK40010154B (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
NZ792363A (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
HK40043784A (en) Bispecific anti claudin xcd3 antibodies for treatment of claudin expressing cancer diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210602

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210602

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220406

R150 Certificate of patent or registration of utility model

Ref document number: 7055794

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250